Physician profile
Andy Robert Welstead
NPI 1508126756
$5,167.90
in general payments reported to CMS, 2019-2025
46 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $276 · 2021: $166 · 2022: $793 · 2023: $1,181 · 2024: $1,013 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $845.21 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $627.18 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $427.07 | 2022-2025 | |
| Novo Nordisk INC | $355.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $322.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.08 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $186.65 | 2021-2025 | |
| Astellas Pharma US INC | $183.32 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $166.24 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $147.76 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $143.87 | 2019-2025 | Bydureon, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $110.43 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $88.74 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Teva Pharmaceuticals USA, INC. | $87.39 | 2023-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $75.72 | 2020-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Welstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.